InflaRx (NASDAQ:IFRX) Issues Quarterly Earnings Results

InflaRx (NASDAQ:IFRX) announced its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.08, FiscalAI reports.

InflaRx Trading Up 26.9%

Shares of InflaRx stock traded up $0.53 on Wednesday, hitting $2.50. 18,208,689 shares of the company traded hands, compared to its average volume of 1,612,826. The stock’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.12. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.86. The company has a market cap of $180.73 million, a PE ratio of -3.29 and a beta of 2.42.

Institutional Trading of InflaRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of InflaRx during the fourth quarter valued at approximately $135,000. Suvretta Capital Management LLC raised its stake in shares of InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after acquiring an additional 1,450,000 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of InflaRx during the fourth quarter valued at approximately $104,000. Squarepoint Ops LLC raised its stake in shares of InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock valued at $328,000 after acquiring an additional 135,826 shares in the last quarter. Finally, HRT Financial LP bought a new stake in shares of InflaRx during the fourth quarter valued at approximately $47,000. Institutional investors own 42.39% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Guggenheim reissued a “buy” rating and issued a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. Oppenheimer assumed coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.80.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.